Entrada Therapeutics, Inc.

NasdaqGM TRDA

Entrada Therapeutics, Inc. Free Cash Flow Yield on January 14, 2025: -3.74%

Entrada Therapeutics, Inc. Free Cash Flow Yield is -3.74% on January 14, 2025, a -112.78% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Entrada Therapeutics, Inc. 52-week high Free Cash Flow Yield is 37.71% on March 12, 2024, which is 1,108.99% above the current Free Cash Flow Yield.
Entrada Therapeutics, Inc. 52-week low Free Cash Flow Yield is -25.78% on April 30, 2024, which is -589.94% below the current Free Cash Flow Yield.
Entrada Therapeutics, Inc. average Free Cash Flow Yield for the last 52 weeks is -0.63%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGM: TRDA

Entrada Therapeutics, Inc.

CEO	Mr. Dipal Doshi
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	6 Tide Street
Employees	177
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years